Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Sussman

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
JAMA Network Open|April 13, 2026
Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia GravisJoseph Lord, Matthew Walton, Peter Murphy, et al.
The Cochrane Database of Systematic Reviews|July 8, 2025
Complement inhibitors for myasthenia gravis in adultsLaura M White, Fiona J Clay, Anne-Marie Forbes, et al.
The Cochrane Database of Systematic Reviews|August 22, 2025
FcRn inhibitors for myasthenia gravisLaura M White, Fiona J Clay, Anne-Marie Forbes, et al.
Practical Neurology|September 12, 2025
Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)Saiju Jacob, Maria Elena Farrugia, Channa Hewamadduma, et al.
Neuromuscular Disorders : NMD|April 16, 2024
Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravisKatherine C Dodd, Rohan Ahmed, Philip Ambrose, et al.
The Cochrane Database of Systematic Reviews|July 3, 2025
Rituximab for myasthenia gravisKatherine C Dodd, Fiona J Clay, Anne-Marie Forbes, et al.
Med (New York, N.Y.)|February 7, 2026
Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravisKatherine C Dodd, Kirsten Baillie, James K L Holt, et al.
BMJ (Clinical Research Ed.)|November 18, 2010
Open letter to prime minister David Cameron and health secretary Andrew LansleyDavid J Nicholl, David Hilton-Jones, Jacqueline Palace, et al.
Molecular Medicine (Cambridge, Mass.)|November 13, 2015
Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of <i>TNFRSF11A</i> and Identification of <i>ZBTB10</i> and Three Distinct HLA AssociationsMichael F Seldin, Omar K Alkhairy, Annette T Lee, et al.
Annals of Neurology|October 12, 2012
Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08Peter K Gregersen, Roman Kosoy, Annette T Lee, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
JAMA Network Open|April 13, 2026
Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia GravisJoseph Lord, Matthew Walton, Peter Murphy, et al.
The Cochrane Database of Systematic Reviews|July 8, 2025
Complement inhibitors for myasthenia gravis in adultsLaura M White, Fiona J Clay, Anne-Marie Forbes, et al.
The Cochrane Database of Systematic Reviews|August 22, 2025
FcRn inhibitors for myasthenia gravisLaura M White, Fiona J Clay, Anne-Marie Forbes, et al.
Practical Neurology|September 12, 2025
Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)Saiju Jacob, Maria Elena Farrugia, Channa Hewamadduma, et al.
Neuromuscular Disorders : NMD|April 16, 2024
Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravisKatherine C Dodd, Rohan Ahmed, Philip Ambrose, et al.
The Cochrane Database of Systematic Reviews|July 3, 2025
Rituximab for myasthenia gravisKatherine C Dodd, Fiona J Clay, Anne-Marie Forbes, et al.
Med (New York, N.Y.)|February 7, 2026
Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravisKatherine C Dodd, Kirsten Baillie, James K L Holt, et al.
BMJ (Clinical Research Ed.)|November 18, 2010
Open letter to prime minister David Cameron and health secretary Andrew LansleyDavid J Nicholl, David Hilton-Jones, Jacqueline Palace, et al.
Molecular Medicine (Cambridge, Mass.)|November 13, 2015
Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of <i>TNFRSF11A</i> and Identification of <i>ZBTB10</i> and Three Distinct HLA AssociationsMichael F Seldin, Omar K Alkhairy, Annette T Lee, et al.
Annals of Neurology|October 12, 2012
Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08Peter K Gregersen, Roman Kosoy, Annette T Lee, et al.
Pageof 4